Search Within

David Hyman

Formats
  1. Meeting Abstract (174)
  2. Journal Article (170)
  3. Review (4)
  4. Research Letter (3)
  5. Editorial (2)
  6. Book Section (1)
Groups
  1. Department of Medicine (354)
  2. Early Drug Development Service (354)
  3. Solid Tumor Oncology Division (354)
  4. GSK Faculty (210)
  5. Department of Pathology and Laboratory Medicine (167)
  6. Human Oncology and Pathogenesis Program (167)

More Groups

People
  1. David Solit (107)
  2. Michael Berger (105)
  3. Marc Ladanyi (81)
  4. Alexander Drilon (78)
  5. Ahmet Zehir (75)
  6. Jose Baselga (68)

More People

Years
  1. 2024 (1)
  2. 2022 (4)
  3. 2021 (9)
  4. 2020 (44)
  5. 2019 (74)
  6. 2018 (57)

More Years

Publications
  1. Journal of Clinical Oncology (81)
  2. Cancer Research (32)
  3. Clinical Cancer Research (26)
  4. Annals of Oncology (22)
  5. Blood (19)
  6. Cancer Discovery (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (94)
  2. American Association for Cancer Research (82)
  3. Oxford University Press (26)
  4. Nature Publishing Group (23)
  5. American Society of Hematology (20)
  6. Elsevier Inc. (13)

More Publishers

Results (354)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib efficacy and safety in adult TRK fusion cancer patients
    Meeting Abstract

    Hong, D. S.; Kummar, S.; Farago, A. F.; Lassen, U. N.; Berlin, J.; Schilder, R. J.; McDermott, R. S.; Patel, J. D.; Dowlati, A.; Doebele, R. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study)
    Meeting Abstract

    Cho, B. C.; Drilon, A. E.; Doebele, R. C.; Kim, D. W.; Lin, J. J.; Lee, J.; Ahn, M. J.; Zhu, V. W.; Ejadi, S.; Camidge, D. R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Benefit of early-phase targeted, basket, and immune-based trials for patients with chemorefractory gastrointestinal (GI) cancers
    Meeting Abstract

    Agarwal, R.; Cangemi, N. A.; Epstein, A. S.; Harding, J. J.; Segal, N. H.; Reidy, D. L.; Hyman, D. M.; Saltz, L. B.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical validation of a genomics-based classifier to predict tissue of origin from targeted tumor sequencing
    Meeting Abstract

    Zheng, Y.; Penson, A. V.; Camacho, N.; Biederstedt, E.; Zehir, A.; Kandoth, C.; Syed, A.; Varghese, A. M.; Al-Ahmadie, H. A.; Schultz, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
    Meeting Abstract

    Won, H. H.; Selcuklu, S. D.; Piha-Paul, S. A.; Saura, C.; Rodon, J.; Mayer, I. A.; Loi, S.; Shapiro, G. I.; Lu, J.; Brufsky, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Initial results from the phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors
    Meeting Abstract

    Schram, A.; Spreafico, A.; Oliva, M.; Brana, I.; Garralda, E.; Lakhani, N.; Von Hoff, D.; Borazanci, E.; Pandya, N.; Hoffman, K.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Prospective clinical sequencing distinguishes independent primary cancers from recurrent or metastatic disease
    Meeting Abstract

    Schram, A. M.; Bandlamudi, C.; Zehir, A.; Ladanyi, M.; Berger, M. F.; Taylor, B. S.; Hyman, D. M.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • BRCA-mediated tumorigenesis is origin and cell-type dependent
    Meeting Abstract

    Jonsson, P.; Cheng, M. L.; Bandlamudi, C.; Srinivasan, P.; Chavan, S. S.; Friedman, N. D.; Rosen, E. Y.; Richards, A. L.; Bouvier, N.; Selcuklu, S. D.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study
    Meeting Abstract

    Hyman, D.; Hendifar, A.; Chung, H. C.; Maio, M.; Leary, A.; Spanggaard, I.; Rhee, J.; Marton, M.; Chen, M.; Krishnan, S.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)
    Meeting Abstract

    Hyman, D.; Kummar, S.; Farago, A.; Geoerger, B.; Mau-Sorensen, M.; Taylor, M.; Garralda, E.; Nagasubramanian, R.; Natheson, M.; Song, L.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save